文献速递心力衰竭与心肌病心律失常

可穿戴心脏复律除颤器在非缺血性心肌病患者的荟萃分析

Wearable cardioverter-defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis.
PubMed 文献 · Heart · 2026-03-09

NICM患者适当电击率为1%(87/7708;95%CI 1%至2%),心肌炎为2%(16/1049;95%CI 1%至2%),围产期心肌病为3%(7/183;95%CI 0%至20%),Takotsubo综合征为2%(2/102;95%CI 0%至7%),先天性/遗传性或基因心肌病为1%(8/594;95%CI 1%至3%)。不适当电击范围为0%至1%。结论认为NICM患者在决定是否符合ICD植入条件前的药物优化期面临显著的SCD风险。

要点

  • 新诊断NICM患者药物优化期使用WCD的适当电击率为1%。
  • 不同亚型适当电击率:心肌炎2%、围产期心肌病3%、Takotsubo综合征2%、遗传性心肌病1%。
  • 不适当电击率范围为0%至1%,随访结束时ICD植入率6%至43%。

核心结论

  • NICM患者在药物优化期、决定是否具备ICD植入资格前,面临显著的SCD风险。
  • 本荟萃分析基于非对照研究,但WCD记录并发放的适当电击评估高度可靠。

研究设计与样本

  • 系统综述,检索Medline、Embase和Cochrane Library,最后更新至2025年3月。
  • 由两名评价者独立进行研究选择、质量评估和数据提取,采用随机效应模型合并数据。

主要发现

  • NICM患者适当电击率为1%(87/7708;95%CI 1%至2%)。
  • 心肌炎患者适当电击率为2%(16/1049;95%CI 1%至2%)。
  • 围产期心肌病患者适当电击率为3%(7/183;95%CI 0%至20%)。
  • Takotsubo综合征患者适当电击率为2%(2/102;95%CI 0%至7%)。
  • 先天性/遗传性或基因心肌病患者适当电击率为1%(8/594;95%CI 1%至3%)。

临床怎么用

  • 对于新诊断NICM患者,在药物优化期可考虑使用WCD以应对潜在的SCD风险。
  • WCD记录的适当电击可作为持续性室性心律失常的可靠替代指标,用于评估风险。

局限性

  • 结果基于非对照观察性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Optimisation of medical therapy is recommended for patients with newly diagnosed non-ischaemic cardiomyopathies (NICM) before consideration of a primary preventive implantable cardioverter-defibrillator (ICD). During this optimisation period, patients face a potentially elevated risk for sudden cardiac death (SCD) that can be countered with a wearable cardioverter-defibrillator (WCD). This systematic review aims to assess the risk for SCD in patients with newly diagnosed NICM. METHODS: A systematic review was performed in Medline, Embase and Cochrane Library last updated on March 2025. Studies with patients aged ≥18 years with newly diagnosed NICM (≤90 days) who were recipients of WCD were included. Study selection, study quality assessment and data extraction were performed by two reviewers independently. Data on percentage of patients with appropriate WCD shocks (as proxy for sustained ventricular arrhythmia, potentially leading to SCD), inappropriate WCD shocks and device implantation were pooled by random-effects model. RESULTS: 50 non-controlled observational studies were included, comprising a total of 10 066 patients with NICM. The percentage of appropriate shocks was 1% (87/7708; 95% CI 1% to 2%) in patients with NICM, 2% (16/1049; 95% CI 1% to 2%) in patients with myocarditis, 3% (7/183; 95% CI 0% to 20%) in peripartum cardiomyopathy, 2% (2/102; 95% CI 0% to 7%) in Takotsubo syndrome and 1% (8/594; 95% CI 1% to 3%) for congenital/inherited or genetic cardiomyopathy. Inappropriate shocks ranged from 0% to 1%. At the end of follow-up, between 6% (Takotsubo syndrome) and 43% (congenital/inherited or genetic cardiomyopathy) of patients received an ICD. CONCLUSION: Patients with NICM face a significant risk of SCD during the drug optimisation period before deciding if they qualify for ICD implantation. Results of this meta-analysis are based on non-comparative studies; however, the assessment of an appropriate shock delivered and recorded by the WCD is highly reliable. PROSPERO REGISTRATION NUMBER: CRD42024555879.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Providência R, Salih A, Aidelsburger P, et al. Wearable cardioverter-defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis. Heart. 2026. PMID: 41802849. doi:10.1136/heartjnl-2025-326956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。